Results 91 to 100 of about 786,579 (199)
Cancer vaccines: uses of HLA transgenic mice compared to genetically modified mice [PDF]
Many tumor antigens have been identified that can be targeted by the immune system. Animal models that have been genetically modified to express human HLA molecules instead of their own MHC antigens have shown to be valuable in the discovery of peptides ...
McArdle, SE
core
Natural killer (NK) cells play a crucial role in immune surveillance by recognizing and eliminating tumor cells. However, tumors employ various mechanisms to evade NK cell-mediated immunity.
Jong-Tae Kim +6 more
doaj +1 more source
Gestational hypothyroxinemia (HTX) is associated with cognitive impairments and autism traits in offspring. However, the underlying mechanisms remain unclear.
Enrique González-Madrid +15 more
doaj +1 more source
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands [PDF]
Christine M. Cramer‐van der Welle +14 more
openalex +1 more source
The importance of early immunotherapy in patients with faciobrachial dystonic seizures. [PDF]
Faciobrachial dystonic seizures and limbic encephalitis closely associate with antibodies to leucine-rich glioma-inactivated 1 (LGI1). Here, we describe 103 consecutive patients with faciobrachial dystonic seizures and LGI1 antibodies to understand ...
Bi, Mian +15 more
core
Gefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients harboring EGFR mutation.
Shuman Zhen +12 more
doaj +1 more source
Despite recent advancements in immunotherapy, most cancer patients still struggle to achieve sustained benefits, highlighting the need for new treatment strategies.
Yee Peng Phoon +9 more
doaj +1 more source
TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY [PDF]
Melissa A. Galati +18 more
openalex +1 more source

